Home
overview
Cytokines are implicated in many major diseases including cancer, multiple sclerosis, asthma and autoimmune and inflammatory diseases. Increasingly, cytokine-based drugs and anti-cytokines are playing a crucial role in the treatment and management of these diseases. Consequently, the market for these drugs is expanding, providing enormous commercial and therapeutic potential.

This conference will look at the development of new cytokine-based drugs, new uses for existing drugs and the role these drugs can play in treating disease. It will explain how the study of genomics is being applied to discover genes that express cytokines and identify cytokine inhibitors and regulatory pathways.

Cytokines as Drug Targets & Therapeutics covers up to the minute clinical developments concerning the major classes of cytokine and chemokines. It also provides fascinating case studies of how pharmaceutical and biotechnology companies are researching and developing cytokine-based drugs and identifying new cytokine targets.

As a senior industry executive, you will be aware of the importance and potential of this field. I am therefore inviting you to register for SMi’s Cytokines as Drug Targets & Therapeutics. This conference is organised and produced by SMi: we specialise in providing senior executives with timely, strategic and focused up to date information. SMi conferences are leading-edge business events offering delegates the opportunity to meet senior industry figures and seek their advice and opinions.

Please register now to guarantee your place at this important conference.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Gerry Graham

Dr Gerry Graham, Group Head, Senior Scientist, CRC Beatson Institute for Cancer Research

9:10 BRINGING CYTOKINE BASED THERAPIES TO THE MARKET

Dr Jeltje Schulten

Dr Jeltje Schulten, Platform Manager, Merck KGaA

  • The global marketplace for cytokine therapies
  • Cytokine based therapies in development: targeted cytokine therapies
  • Immunocytokines: targeted antibody linked to cytokine
  • Considerations for bringing immunocytokines to the market
  • Strategies for marketing immunocytokines
  • Commercialisation of immunocytokine technology; Developing the market
  • 9:40 CHEMOKINES FROM THE NON-LEUKOCENTRIC VIEW POINT

    Dr Gerry Graham

    Dr Gerry Graham, Group Head, Senior Scientist, CRC Beatson Institute for Cancer Research

  • MIP-1alpha as a proliferative regulator
  • Chemokine receptors in diverse functional contexts
  • ESkine/PESKY, a novel paradigm for chemokine function
  • Views to the future: what are the key issues in chemokine and chemokine receptor biology and biochemistry?
  • 10:20 DEVELOPING A LOW DOSAGE THERAPEUTIC INTERFERON

    Dr Philip C Fox

    Dr Philip C Fox, Director, Research & Development, Amarillo Biosciences

  • Developing low dose, orally-administered dosage forms of interferon
  • Providing therapeutic benefit with improved patient convenience
  • Systemic effects of orally-administered interferon
  • IFN-alpha in autoimmunity and HIV opportunistic infection
  • Gaining orphan drug status for IFN-alpha
  • 11:00 Morning Coffee

    11:20 TNF BINDING PROTEIN

    Dr Arnaud Ythier

    Dr Arnaud Ythier, Corporate Vice President, Experimental Medicine, Serono International

  • Pre-clinical pharmacology
  • Pharmacokinetics
  • Clinical indications
  • 12:00 TARGETING INTERLEUKINS FOR TREATMENT OF INFLAMMATORY DISEASE

    Dr Geoffrey Davis

    Dr Geoffrey Davis, Chief Scientific Officer, Abgenix

  • Providing evidence of the role of IL-8 in various inflammatory diseases
  • Generating human antibodies using transgenic mouse technology
  • Developing ABX-IL8 using XenoMouse™ technology
  • ABX-IL8: moving into phase II clinical trials
  • Commercialising strategies for antibody therapies for inflammatory and autoimmune diseases
  • 12:40 Networking Lunch

    13:40 TARGETING TUMOUR NECROSIS FACTOR (TNF)

    Dr James Glover

    Dr James Glover, Head of Immunosciences, Protherics

  • The role of TNF-alpha, a pro-inflammatory cytokine
  • Research strategies for anti-cytokine therapeutics
  • Developing CytoTAb™ for neutralising TNF-alpha
  • Potential of CytoTAb™ in treating Sepsis Syndome
  • Targeting TNF-alpha in the future
  • 14:20 DISCOVERING NOVEL AND RARE GENES EXPRESSING CYTOKINES

    Dr John Ford

    Dr John Ford, Vice President, Functional Genomics, Hyseq

  • Defining a rarely-expressed gene
  • Clinical significance of rarely-expressed genes: why are they attractive biopharmaceutical candidates?
  • Anti-inflammatory IL-1Hy1: product candidate for treating inflammatory disease
  • Therapeutic applications of IL-1Hy1
  • Clinical development of IL-1Hy1
  • 15:00 CYTOKINES AND CYTOKINE RECEPTOR GENE DISCOVERY: FROM SEQUENCE TO THERAPEUTIC

    Dr Kevin Baker

    Dr Kevin Baker, Group Leader, Department of Molecular Biology, Human Genome Sciences

  • Genomic approaches to new target discovery
  • Therapeutic opportunities for intervention based on cytokine function
  • Cytokines for treating immune deficiency syndromes
  • Cytokine based therapies for autoimmune disease
  • 15:40 Afternoon Tea

    16:00 GENOMICS, CYTOKINES AND INFLAMMATORY DISEASE

    Dr David Anderson

    Dr David Anderson, Chief Scientific Officer, Signal Research Division of Celgene

  • Developing and integrating a platform of target and drug discovery technologies
  • Accelerating the application of genomics to the discovery of new classes of gene regulating drugs
  • Generating drug leads with disease-modifying activity in immune-inflammatory disease
  • Identifying potent and selective inhibitors of the NF-K(beta) pathway that regulates cytokine genes
  • 16:30 TARGETING CHEMOKINES IN ALLERGIC RESPONSES

    Dr Tristan Vaughan

    Dr Tristan Vaughan, Principal Scientist, Cambridge Antibody Technology

  • Chemokines as a target
  • Eotaxin and eosinophils
  • Development of CAT-213 anti-eotaxin 1 human mAb
  • Potential clinical indications for CAT-213
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    17:10 Networking drinks reception

    8:30 Re-registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Charles de Wet

    Dr Charles de Wet, Medical Director, Boehringer Ingelheim

    9:10 CYTOKINE TRAPS

    Dr Neil Stahl

    Dr Neil Stahl, Vice President, Preclinical Development & Biomolecular Science, Regeneron

  • Current development programmes: interleukin traps for rheumatoid arthritis, asthma and allergies
  • Researching and developing cytokine traps; Searching for novel human therapeutics
  • Insights into the receptor and signal transduction mechanism of the cytokine family
  • Immunological benefits of human-derived cytokine antagonists
  • Therapeutic importance of cytokine traps
  • The role of molecular and cellular research in improving and modifying cytokine trap technology
  • 9:40 THALOMID AND ANALOGUES AS CYTOKINE MODULATORS

    Dr David Stirling

    Dr David Stirling, Chief Scientific Officer, Executive Vice President, Pharmaceutical Research & Development, Celgene

  • TNF and its over-production: the link to chronic inflammatory diseases
  • THALOMID: a TNF inhibitor
  • Developing SelCIDs and IMiDs
  • Mechanism of action
  • Potential uses in inflammatory disease and oncology
  • Clinical development of THALOMID and analogues
  • 10:20 INTERLEUKIN THERAPY FOR CANCER

    Dr Eyal Talor

    Dr Eyal Talor, Senior Vice President, Research & Manufacturing, Cel-Sci

  • Development of MultiKine: a leucocyte interleukin injection
  • Mechanism of action
  • Inducing tumour reduction and necrosis
  • Creating a synergistic effect by combining cytokine families
  • Providing a three pronged approach to tumour treatment: tumouricidal cytokine, chemokines and pro-inflammatory cytokines
  • Increasing efficacy through mode of administration
  • 11:00 Morning Coffee

    11:20 TRANSFORMING GROWTH FACTOR BETA AS A TARGET

    Dr David Glover

    Dr David Glover, Medical Director, Cambridge Antibody Technology

  • Transforming growth factor (TGf-beta) as a target
  • TGF-beta-1, TGF-beta-2 and fibrosis/scarring
  • Developing CAT-152 & CAT-192
  • Clinical trial results of CAT-152 in glaucoma surgery
  • Therapeutic potential of CAT-152 and CAT-192
  • 12:00 ANTIBODIES TO THE TYPE-1 INTERFERON

    Dr Christopher Bebbington

    Dr Christopher Bebbington, Senior Director, Biology Research, Coulter Pharmaceutical

  • Developing an antibody-based approach to target the receptor for type 1 interferons for treatment of autoimmune disorders and transplant rejection
  • Pre-clinical data with a murine antibody, 64G12, directed against the IFNAR1 receptor polypeptide
  • Development and characterisation of an engineered human antibody against IFNAR1
  • 12:40 Networking Lunch

    14:00 COLLABORATING TO DEVELOP ASTHMA THERAPIES

    Dr Roy Clifford Levitt

    Dr Roy Clifford Levitt, Executive Vice President, Chief Operating Officer, Magainin Pharmaceuticals

  • Genetics of asthma
  • Interleukin-9: validation as a target
  • IL-9 receptor as a key second gene candidate
  • Action of IL-9IL9R in asthmatic lung inflammation
  • Developing novel therapeutics for asthma and allergy utilising optimal biologic gene targets
  • 14:40 TARGETING THE MEDIATORS OF CHRONIC INFLAMMATION

    Dr Douglas Williams

    Dr Douglas Williams, Executive Vice President, Chief Technical Office, Immunex

  • Developing Enbrel: an etanercept
  • Evaluating its potential role in a variety of disease states
  • Etanercept: a dimeric fusion protein; Mechanism of action
  • Pharmacokinetics and pharmacodynamics
  • Cytokines/cytokine receptors in the pipeline
  • Exploring the usefulness of cytokines and cytokine antagonists in disease management
  • 15:20 Afternoon Tea

    15:40 INHIBITING TNF-ALPHA AT THE TRANSLATIONAL LEVEL

    Dr Roland Buelow

    Dr Roland Buelow, Senior Vice President Discovery Research, SangStat

  • TNF-alpha: a cytokine triggering activation of immune response and inflammation
  • Developing RDP58: a small molecule to inhibit TNF-alpha synthesis
  • Rational design of immunomodulatory peptides
  • Inhibition of TNF synthesis by RDP58
  • Efficacy in animal models, including monkeys
  • Toxicity and pharmacokinetics
  • 16:20 IMPROVING THE IMMUNE SYSTEM

    Dr Kurt Gehlsen

    Dr Kurt Gehlsen, Vice President, Development & Chief Technical Officer, Maxim Pharmaceuticals

  • Improving immunotherapy by protecting critical immune cells
  • Administering Maxamine™ in combination with cytokines
  • Advantages of combination therapy involving interferon
  • Results from malignant melanoma trials
  • Evaluating safety and efficacy of combined immunotherapy with IL-2 and IF-2b
  • Meeting unmet medical needs in malignant melanoma
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.